Similarly, Kerk et al. [149] demonstrated the ability of using an antibody-drug conjugate (ADC) to target the 5T4 oncofetal antigen known as MEDI0641 and reduce CD44 and ALDH cell populations, as well as reduce tumor growth and prevent tumor recurrence in an in vivo model of HNSCC. The gene discussed is CD44; the disease is neoplasm.